@article{c0b4dab1822a4f2794b296a7564c7c77,
title = "Brain Lewy-Type Synucleinopathy Density Is Associated with a Lower Prevalence of Atherosclerotic Cardiovascular Disease Risk Factors in Patients with Parkinson's Disease",
abstract = "Background: Some epidemiology studies suggest that atherosclerotic cardiovascular disease (ASCVD) risk factors increase the risk of developing Parkinson's disease (PD). However, conflicting data suggest lower rates of ASCVD in PD. Objective: The objective of this study is to determine, with data from a longitudinal clinicopathological study, whether ASCVD risk factors are associated with a PD diagnosis and/or increased brain or peripheral load of Lewy-type synucleinopathy (LTS). Methods: All subjects were followed to autopsy and neuropathological examination in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Multivariable regression models, including age, gender, and smoking history, were used to investigate the association of a PD diagnosis or brain or submandibular gland LTS load with ASCVD risk factors. Results: 150 subjects were included (PD n=60, controls n=90). Univariable comparisons and regression models showed a general trend to inverse associations. The multivariable odds ratio (OR) of brain LTS load for carotid artery disease was 0.93 (95% CI: 0.86 to 0.98; p=0.02), for anticoagulant use 0.95 (95% CI: 0.90 to 0.99; p=0.04) and for abnormal heart weight 0.96 (95% CI: 0.92 to 0.99; p=0.01). Composite clinical and overall (clinical + pathology composite risk scores) composite risk scores were also significantly lower in the PD subjects (p=0.0164 and 0.0187, respectively). Submandibular gland LTS load was not significantly related to ASCVD conditions. Conclusions: This study shows associations of higher brain LTS with lower prevalence of both clinical and pathological indices of ASCVD in PD subjects versus age-similar controls. We suggest that this is due to α-synuclein pathology-induced sympathetic denervation in PD.",
keywords = "Parkinson's disease, atherosclerotic cardiovascular disease, sympathetic nervous system, α-synuclein",
author = "Driver-Dunckley, {Erika D.} and Nan Zhang and Adler, {Charles H.} and Serrano, {Geidy E.} and Sue, {Lucia I.} and Shill, {Holly A.} and Mehta, {Shyamal H.} and Belden, {Christine M.} and Zamrini, {Edward Y.} and Kathryn Davis and Beach, {Thomas G.}",
note = "Funding Information: The Brain and Body Donation Program has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson{\textquoteright}s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer{\textquoteright}s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer{\textquoteright}s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson{\textquoteright}s Disease Consortium) and the Michael J. Fox Foundation for Parkinson{\textquoteright}s Research. Funding Information: Financial Disclosures for the previous 12 months: received research funding from the National Institutes of Health (P30 AG19610), the Michael J. Fox Foundation for Parkinson{\textquoteright}s Research, Department of Health and Human Services of the State of Arizona, Avid Radiopharmaceuticals, Navidea Bio-pharmaceuticals and Aprionoia Therapeutics. EYZ Funding Sources and Conflict of Interest: No specific funding was received for this work. Funding Information: Financial Disclosures for the previous 12 months: The author declares that there are no additional disclosures to report. HAS For this work: received research support from the NIH, the Michael J. Fox Foundation for Parkinson Research and the Arizona Biomedical Research Foundation. Funding Information: Financial Disclosures for the previous 12 months: I have had consulting relationships with Abbvie and Sunovion in the past 12 months. TGB Funding Sources and Conflict of Interest: Specific funding relating to this work was received from the National Institutes of Health (U24 NS072026; P30 AG19610) and the Michael J Fox Foundation for Parkinson{\textquoteright}s Research.",
year = "2019",
doi = "10.3233/JPD-191610",
language = "English (US)",
volume = "9",
pages = "543--552",
journal = "Journal of Parkinson's disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "3",
}